What is the 10-year survival rate for Ductal Carcinoma In Situ (DCIS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The ten-year survival rate for patients with Ductal Carcinoma In Situ (DCIS) is approximately 94% for low-risk patients and 83% for intermediate- and high-risk patients when treated with lumpectomy alone, as reported in a retrospective review 1. This high survival rate reflects the non-invasive nature of DCIS, which is considered a stage 0 breast cancer confined within the milk ducts without spreading to surrounding breast tissue. Some key points to consider include:

  • Treatment typically involves surgical removal through lumpectomy (breast-conserving surgery) or mastectomy, often followed by radiation therapy for those who undergo lumpectomy.
  • Some patients may also receive hormonal therapy such as tamoxifen or aromatase inhibitors for 5-10 years if their DCIS is estrogen receptor-positive, which further reduces recurrence risk.
  • Despite the excellent prognosis, approximately 10-15% of patients may experience a recurrence within 10 years, with about half of these recurrences being invasive breast cancer.
  • Regular follow-up mammograms and clinical breast exams are essential for early detection of any recurrence. The high survival rate underscores why DCIS is sometimes referred to as pre-cancer rather than cancer, though proper treatment remains important to prevent progression to invasive disease, with a 20-year breast cancer mortality rate after treatment of DCIS as low as 3% 1.

From the Research

Ten-Year Survival with DCIS

  • The ten-year breast cancer-specific survival rate for DCIS is reported to be 97-98% with the current treatment approach 2.
  • A study found that the 10-year relapse-free survival rate for DCIS patients treated with mastectomy is 97% 3.
  • Another study reported a 10-year disease-free survival rate of 98% for patients treated with mastectomy and 81% for those treated with excision and radiation therapy 4.
  • The 10-year disease-specific survival (DSS) rates were found to be highest in lumpectomy with radiation (98.9%), followed by mastectomy (98.5%), and lumpectomy alone (98.4%) 5.
  • While the specific ten-year survival rate is not mentioned in the study, it is noted that the actuarial 15-year breast cancer mortality rate was 2.33% for patients treated with lumpectomy alone, 1.74% for patients treated with lumpectomy and radiation, and 2.26% for patients treated with mastectomy 6.

Treatment Options and Survival

  • The choice of surgical procedure and adjuvant therapy does not significantly influence breast cancer death in DCIS patients without micrometastasis 2.
  • Lumpectomy with radiation therapy is associated with a significant reduction in breast cancer mortality compared to lumpectomy alone or mastectomy alone 6.
  • The use of radiotherapy is associated with reduced risk of breast cancer mortality in patients with DCIS 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.